KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have received a consensus rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $24.83.

Several brokerages have recently issued reports on KALV. Jones Trading reaffirmed a “buy” rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th.

Insider Buying and Selling

In related news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the firm’s stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the completion of the acquisition, the insider now owns 5,303,985 shares of the company’s stock, valued at $49,963,538.70. This trade represents a 0.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $32,867.84. Following the sale, the insider now directly owns 106,611 shares in the company, valued at $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,730 shares of company stock valued at $102,226 over the last three months. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in KALV. SG Americas Securities LLC boosted its holdings in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,319 shares in the last quarter. AlphaQuest LLC boosted its holdings in KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company’s stock valued at $150,000 after purchasing an additional 2,588 shares in the last quarter. Intech Investment Management LLC boosted its holdings in KalVista Pharmaceuticals by 58.5% during the fourth quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company’s stock valued at $146,000 after purchasing an additional 6,349 shares in the last quarter. Vanguard Group Inc. boosted its holdings in KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after purchasing an additional 104,716 shares in the last quarter. Finally, Schroder Investment Management Group raised its stake in shares of KalVista Pharmaceuticals by 86.8% in the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after acquiring an additional 374,213 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $14.76 on Thursday. The company has a market capitalization of $733.81 million, a price-to-earnings ratio of -4.05 and a beta of -0.01. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $15.50. The company’s fifty day moving average price is $12.15 and its two-hundred day moving average price is $10.66.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).